Morphological analysis of pancreatic adenocarcinoma on multidetector row computed tomography: Implications for treatment response evaluation

Pancreas

Volumn 38, Issue 7, 2009, Pages 799-803

  Rezai, Pedram ^a   Mulcahy, Mary F ^a   Tochetto, Sandra M ^a   Berggruen, Senta ^a   Yaghmai, Vahid ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

MDCT; Oncology; Pancreatic adenocarcinoma; Segmentation; Tumor morphology; Volumetry

Indexed keywords

BEVACIZUMAB; GEMCITABINE; IOHEXOL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MALE; MORPHOLOGY; MULTIDETECTOR COMPUTED TOMOGRAPHY; ONCOLOGY; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR VOLUME;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II AS TOPIC; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RADIOTHERAPY; REPRODUCIBILITY OF RESULTS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 70349923194     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3181ac7511     Document Type: Article

References (33)

1. Fitzgerald TL, Hickner ZJ, Schmitz M, et al. Changing incidence of pancreatic neoplasms: a 16-year review of statewide tumor registry. Pancreas. 2008;37:134-138.
2. Gralow J, Ozols RF, Bajorin DF, et al. Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening-a report from the American Society of Clinical Oncology. J Clin Oncol. 2008;26:313-325.
3. Bradley EL 3rd. Long-term survival after pancreatoduodenectomy for ductal adenocarcinoma: the emperor has no clothes? Pancreas. 2008; 37:349-351.
4. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
5. James K, Eisenhauer E, Christian M, et al. Measuring response in solid tumors: unidimensional versus bidimensional measurement. J Natl Cancer Inst. 1999;91:523-528. (Pubitemid 29157060)
6. Suzuki C, Jacobsson H, Hatschek T, et al. Radiologic measurements of tumor response to treatment: practical approaches and limitations. Radiographics. 2008;28:329-344.
7. Boeck S, Wilkowski R, Bruns CJ, et al. Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer. Oncology. 2007;73:221-227. (Pubitemid 351630054)
8. Dragovich T, Burris H 3rd, Loehrer P, et al. Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial. Am J Clin Oncol. 2008;31:157-162.
9. Gharibo M, Patrick-Miller L, Zheng L, et al. A phase II trial of imatinib mesylate in patients with metastatic pancreatic cancer. Pancreas. 2008;36:341-345. (Pubitemid 351591575)
10. Heinrich S, Pestalozzi BC, Schafer M, et al. Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26: 2526-2531.
11. Kindler HL, Friberg G, Singh DA, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2005;23:8033-8040. (Pubitemid 46657405)
12. Kulke MH, Blaszkowsky LS, Ryan DP, et al. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol. 2007;25:4787-4792. (Pubitemid 350086482)
13. Small W Jr, Berlin J, Freedman GM, et al. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol. 2008;26:942-947.
14. Fabel M, von Tengg-Kobligk H, Giesel FL, et al. Semi-automated volumetric analysis of lymph node metastases in patients with malignant melanoma stage III/IV-a feasibility study. Eur Radiol. 2008;18: 1114-1122.
15. Wormanns D, Kohl G, Klotz E, et al. Volumetric measurements of pulmonary nodules at multi-row detector CT: in vivo reproducibility. Eur Radiol. 2004;14:86-92.
16. Yankelevitz DF, Reeves AP, Kostis WJ, et al. Small pulmonary nodules: volumetrically determined growth rates based on CT evaluation. Radiology. 2000;217:251-256.
17. Keil S, Behrendt FF, Stanzel S, et al. Semi-automated measurement of hyperdense, hypodense and heterogeneous hepatic metastasis on standard MDCT slices. Comparison of semi-automated and manual measurement of RECIST and WHO criteria. Eur Radiol. 2008;18: 2456-2465.
18. Kuhnigk JM, Dicken V, Bornemann L, et al. Morphological segmentation and partial volume analysis for volumetry of solid pulmonary lesions in thoracic CT scans. IEEE Trans Med Imaging. 2006;25:417-434.
19. Malvern Instruments: Particle size and shape measurement. November 23, 2005. Available at: www.fei.com/uploadedFiles/Documents/Content/particle- morphology.pdf. Accessed December 10, 2008.
20. Hopper KD, Singapuri K, Finkel A. Body CT and oncologic imaging. Radiology. 2000;215:27-40.
21. Mahr A, Levegrun S, Bahner ML, et al. Usability of semiautomatic segmentation algorithms for tumor volume determination. Invest Radiol. 1999;34:143-150. (Pubitemid 29110716)
22. Van Hoe L, Van Cutsem E, Vergote I, et al. Size quantification of liver metastases in patients undergoing cancer treatment: reproducibility of one-, two-, and three-dimensional measurements determined with spiral CT. Radiology. 1997;202:671-675. (Pubitemid 27093435)
23. Belton AL, Saini S, Liebermann K, et al. Tumour size measurement in an oncology clinical trial: comparison between off-site and on-site measurements. Clin Radiol. 2003;58:311-314. (Pubitemid 36416974)
24. Erasmus JJ, Gladish GW, Broemeling L, et al. Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol. 2003;21:2574-2582. (Pubitemid 46606340)
25. Obuchowski NA. How many observers are needed in clinical studies of medical imaging? AJR Am J Roentgenol. 2004;182:867-869.
26. Schwartz LH, Colville JA, Ginsberg MS, et al. Measuring tumor response and shape change on CT: esophageal cancer as a paradigm. Ann Oncol. 2006;17:1018-1023.
27. Schwartz LH, Mazumdar M, Brown W, et al. Variability in response assessment in solid tumors: effect of number of lesions chosen for measurement. Clin Cancer Res. 2003;9:4318-4323. (Pubitemid 37248386)
28. Benjamin RS, Choi H, Macapinlac HA, et al. We should desist using RECIST, at least in GIST. J Clin Oncol. 2007;25:1760-1764. (Pubitemid 46797958)
29. Gwyther SJ, Schwartz LH. How to assess anti-tumour efficacy by imaging techniques. Eur J Cancer. 2008;44:39-45.
30. Chen W, Delaloye S, Silverman DH, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol. 2007;25:4714-4721. (Pubitemid 350086472)
31. Kelloff GJ, Hoffman JM, Johnson B, et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res. 2005;11:2785-2808. (Pubitemid 40525178)
32. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007;25:5180-5186. (Pubitemid 350232248)
33. Gallagher DJ, Milowsky MI, Bajorin DF. Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting. Cancer. 2008;113:1284-1293.